IPO
Recent changes
- Aug 5, 2026Aug 5, 2026IPO $67.8M Fierce Biotech
- Aug 5, 2026Aug 5, 2026Vogenx Prices $68M IPO for Metabolic Drug Pulse story
- Jul 15, 2026Jul 15, 2026Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | ipo | $67.8M | — | Pulse story |
Latest Pulse
- Aug 5, 2026Vogenx Prices $68M IPO for Metabolic DrugVogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.→
- Jul 15, 2026Jaguar Health, Vogenx Join a Growing Biotech S-1 QueueJaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.→
Coverage Timeline
newest firstAll Coverage
IPO~$67.8M net
Vogenx Prices $68M IPO for Metabolic Drug
Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
Jaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.
Related Companies
Sources & methodologyshow
Where these figures come from
- Fierce BiotechValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.